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Abstract:	22	
	23	
Background:		24	
New-onset	 atrial	 fibrillation	 (AF)	 is	 the	 most	 common	 arrhythmia	 in	 critically	 ill	25	
patients.	Although	evidence	base	and	expert	consensus	opinion	for	management	have	26	
been	 summarised	 in	 several	 international	 guidelines,	 no	 specific	 considerations	 for	27	
critically	 ill	 patients	have	been	 included.	We	aimed	 to	establish	 current	practice	of	28	
management	of	critically	ill	patients	with	new-onset	AF.		29	
Methods:		30	
We	designed	a	short	user-friendly	online	questionnaire.	All	members	of	the	Intensive	31	
Care	 Society	 were	 invited	 via	 email	 containing	 a	 link	 to	 the	 questionnaire,	 which	32	
comprised	21	questions.	The	online	survey	was	conducted	between	November	2016	33	
and	December	2016.	34	
Results:		35	
The	response	rate	was	397/3152	(12.6%).	The	majority	of	respondents	(81.1%)	worked	36	
in	mixed	Intensive	Care	Units	and	were	consultants	(71.8%).	Most	respondents	(39.5%)	37	
would	start	intervention	on	patients	with	fast	new-onset	AF	and	stable	blood	pressure	38	
at	a	heart	rate	between	120	and	139	beats/min.	However,	34.8%	of	participants	would	39	
treat	all	patients	who	developed	new-onset	 fast	AF.	Amiodarone	and	beta-blockers	40	
(80.9%	and	11.6%	of	answers)	were	the	most	commonly	used	treatments.	41	
63.8%	of	respondents	do	not	regularly	anti-coagulate	critically	ill	patients	with	new-42	
onset	 fast	 AF,	 while	 30.8%	 anti-coagulate	 within	 72	 hours.	 68.0%	 of	 survey	43	
respondents	do	not	routinely	use	stroke	risk	scores	in	critically	ill	patients	with	new-44	
onset	AF.		45	
85.4%	 of	 participants	 would	 consider	 taking	 part	 in	 a	 clinical	 trial	 investigating	46	
treatment	of	new-onset	fast	AF	in	the	critically	ill.	47	
Discussion:	48	
Our	 results	 suggest	 a	 considerable	 disparity	 between	 contemporary	 practice	 of	49	
management	of	new-onset	AF	in	critical	illness	and	treatment	recommendations	for	50	
the	 general	 patient	 population	 suffering	 from	 AF,	 particularly	 with	 regard	 to	 anti-51	
arrhythmics	 and	 anticoagulation	 used.	 Amongst	 intensivists,	 there	 is	 a	 substantial	52	
interest	in	research	for	management	of	new-onset	AF	in	critically	ill	patients.		53	
	 	54	
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Strengths	and	limitations	of	this	study:	55	
Strengths:	56	
- A	UK-wide	survey	describing	common	practice	 in	management	of	new-onset	57	
atrial	fibrillation	in	critically	ill	patients	58	
- Identification	of	 a	 research	 interest	 in	 practising	 intensivists	 to	 address	 new	59	
onset	atrial	fibrillation	as	a	common	clinical	problem	in	acutely	ill	patients	60	
- Description	 of	 disparity	 in	 anti-arrhythmic	 strategies	 and	 management	 of	61	
anticoagulation	in	patients	with	new-onset	atrial	fibrillation	62	
Limitations:	63	
- The	low	response	rate	may	limit	generalisability	of	findings	64	
- The	survey	was	limited	to	members	of	the	Intensive	Care	Society	and	may	not	65	
reflect	non-members’	views.	66	
- The	 survey	was	 aimed	 at	 general	 intensivists	without	 specifically	 addressing	67	
management	 of	 perioperative	 or	 cardiac	 patients	 with	 new-onset	 atrial	68	
fibrillation.	69	
	70	
Introduction:	71	
Atrial	 fibrillation	 (AF)	 is	 the	most	 common	 cardiac	 arrhythmia	 in	 both	 the	 general	72	
population	and	the	critical	care	setting	(Makrygiannis	et	al.	2014;	Seguin	et	al.	2004).	73	
New-onset	fast	AF	is	defined	as	atrial	fibrillation	with	a	rapid	ventricular	response	of	74	
more	than	100	beats	per	minute	(bpm)	in	patients	without	a	previous	history	of	atrial	75	
fibrillation.	76	
In	the	past	decades	there	has	been	increased	attention	to	new-onset	AF	in	patients	in	77	
critical	care,	because	it	is	associated	with	a	worse	prognosis	(Chen	et	al.	2015;	Shaver	78	
et	al.	2015).	Evidence	is	growing	that	new-onset	AF	is	associated	with	longer	Intensive	79	
Care	Unit	(ICU)	stay	and	higher	mortality	(Reinelt	2001;	Tseng	et	al.	2016;	Yoshida	et	80	
al.	2015).	Observational	studies	suggested	that	 the	prevalence	of	AF	 in	non-cardiac	81	
medical	ICUs	ranges	from	5	to	26%	(Carrera	et	al.	2016;	Chen	et	al.	2015),	and	affects	82	
up	to	10%	of	patients	in	surgical	ICUs	(Knotzer	et	al.	2000;	Seguin	et	al.	2004).		83	
However,	 despite	 the	 relatively	 high	 incidence	 of	 new-onset	 AF	 among	 critically	 ill	84	
patients,	there	is	paucity	of	evidence	for	its	management	in	the	critical	care	setting.		In	85	
particular,	little	is	known	about	new-onset	AF	in	comparison	to	pre-existing	AF	in	this	86	
subset	of	patients.	Previous	studies	have	mainly	 investigated	the	epidemiology,	risk	87	
factors	 and	 outcomes	 of	 new-onset	 atrial	 fibrillation	 in	 critical	 care,	 while	 little	88	
evidence,	 which	 is	 mainly	 based	 on	 small	 single-centre	 studies	 is	 available	 for	89	
treatment	(Yoshida	et	al.	2015).		90	
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As	a	result,	guidance	on	management	of	AF	is	based	on	the	evidence	obtained	in	the	91	
general	population	and	does	not	include	patients	in	intensive	care.	We	performed	an	92	
online	 survey	 amongst	 practising	 intensivists	 in	 the	 United	 Kingdom	 to	 establish	93	
current	practice	regarding	the	management	of	critically	 ill	patients	developing	new-94	
onset	AF.	We	also	aimed	to	identify	areas	in	which	adherence	to	current	guidance	is	95	
low	and	further	research	is	needed	to	clarify	uncertainties	in	the	treatment	of	these	96	
patients.	97	
	98	
Methods	99	
We	designed	a	short	user-friendly	online	questionnaire	using	Qualtrics®	(Provo,	Utah,	100	
USA)	to	assess	the	knowledge	and	to	explore	the	current	practice	of	British	critical	care	101	
physicians	 in	 managing	 new-onset	 atrial	 fibrillation.	 The	 questionnaire	 was	 pilot-102	
tested	and	revised	based	on	the	question	value.	Where	clinically	relevant,	more	than	103	
one	answer	could	be	given.	104	
Selection	sample	105	
The	survey	population	consisted	of	3152	medical	members	of	Intensive	Care	Society	106	
(ICS),	who	are	practicing	intensive	care	doctors	in	the	UK	and	for	whom	email	contacts	107	
were	available.	We	excluded	critical	care	doctors	who	did	not	practise	or	were	retired.		108	
The	participants	received	an	email	containing	the	link	to	the	questionnaire,	which	was	109	
a	web-based	survey	comprising	of	21	questions	and	developed	using	the	open	source	110	
survey	application	Qualtrics®.	The	online	survey	was	conducted	from	November	2016	111	
to	December	2016.		112	
Questionnaire	113	
The	survey	was	anonymous	and	included	a	consent	form	at	the	beginning	of	the	survey	114	
and	in	the	email	circulated	to	all	participants.	The	consent	form	explained	the	purpose	115	
of	the	study,	the	risks	and	benefits	and	data	management.	The	survey	consisted	of	21	116	
questions,	 which	 were	 divided	 into	 two	 domains.	 The	 first	 domain	 comprised	 7	117	
questions,	 which	 mainly	 recorded	 the	 background	 and	 demographic	 data	 of	 the	118	
responding	physicians	and	their	critical	care	unit.	The	second	domain	had	14	questions	119	
that	aimed	to	identify	current	treatment	strategies	for	critically	ill	patients	with	new-120	
onset	fast	atrial	fibrillation.	The	survey	took	no	more	than	10	minutes	to	complete.		121	
Demographic	 variables	 included	 type	of	 practice	 hospitals	 (district	 general,	 tertiary	122	
referral	centre	or	university	hospital),	the	number	of	patients	admitted	to	the	unit	per	123	
year,	 the	 number	 of	 staffed	 beds	 in	 the	 department,	 the	 case	 mix	 of	 the	 unit	124	
department	(predominantly	surgical,	medical,	mixed	or	specialist	ICU)	as	well	as	the	125	
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level	 of	 training,	 years	 of	 experience	 and	 any	 secondary	 specialty	 of	 the	 survey	126	
participants.		127	
To	identify	and	explore	the	current	practice	in	managing	critically	ill	patients	with	new-128	
onset	 AF,	 participants	 were	 asked	 to	 state	 a	 threshold	 heart	 rate	 at	 which	 they	129	
intervene	 in	 patients	with	 fast	 AF	 and	 stable	 blood	 pressure,	whether	 they	 favour	130	
rhythm	or	rate	control	as	the	primary	treatment	goal,	the	most	commonly	used	anti-131	
arrhythmic	drugs	and	the	reasons	for	their	choice.	Survey	participants	were	also	asked	132	
about	their	treatment	strategy	in	an	example	of	a	critically	ill	patient	with	chest	sepsis	133	
who	developed	new-onset	AF	with	a	heart	rate	of	140-160	beats	per	minute.	In	this	134	
survey	 question,	 participants	were	 given	 options	 of	 different	 treatment	 strategies,	135	
including	 electrolyte	 supplementation,	 Direct	 Current	 (DC)	 cardioversion	 and	 anti-136	
arrhythmic	 drugs.	 Survey	 participants	 were	 requested	 to	 state	 their	 target	 serum	137	
potassium	and	serum	magnesium	level	among	critical	care	patients	with	new-onset	138	
AF.		139	
Finally,	 participants	were	also	asked	about	 their	 anti-coagulation	practice	 including	140	
duration	and	medication	used	and	their	views	on	stroke	risk	assessments	in	critically	141	
ill	 patients	 with	 new-onset	 AF.	 A	 further	 question	 explored	 the	 use	 of	 trans-142	
oesophageal	or	transthoracic	echocardiography	to	guide	treatment.	At	the	end	of	the	143	
survey,	their	views	on	conducting	a	clinical	trial	investigating	treatment	of	new-onset	144	
AF	 in	 this	 subgroup	 of	 patients	 were	 obtained.	 This	 included	 the	 anti-arrhythmic	145	
medications	at	highest	priority	for	investigation	and	acceptability	of	a	placebo	arm	in	146	
a	 research	 study	 investigating	 the	 effectiveness	 of	 anti-arrhythmics	 in	 critically	 ill	147	
patients	with	new-onset	AF.	148	
The	full	content	of	the	survey	is	available	as	a	supplementary	file.	149	
Data	analysis	150	
A	survey	data	report	was	auto-generated	by	Qualtrics®	to	aid	data	analysis.	Descriptive	151	
statistics	 were	 carried	 out	 by	 providing	 absolute	 numbers	 and	 percentages	 of	152	
background	and	demographic	variables	and	 for	all	questions	 relating	 to	knowledge	153	
and	 current	 practice.	 Where	 applicable,	 contingency	 tables	 were	 produced	 and	154	
analysed	using	Fisher’s	exact	test.	To	measure	of	association	between	two	nominal	155	
variables,	 Cramer’s	 V	 was	 used	 and	 interpreted	 as	 follows:	 	 0.1	 –	 0.29	 weak	156	
association,	0.3	–	0.5	moderate	association,	>	0.5	strong	association.			157	
	158	
Results	159	
Demographics	of	survey	participants	160	
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Questionnaires	were	sent	to	3152	members	of	the	Intensive	Care	Society	(ICS)	who	161	
had	updated	email	addresses	available.	We	received	427	responses.	Survey	links	that	162	
had	 been	 opened	without	 provision	 of	 replies	were	 excluded	 from	 the	 study.	 397	163	
complete	 survey	 responses	 were	 obtained	 (12.6%).	 We	 excluded	 30	 surveys	 with	164	
incomplete	answers	on	the	management	of	new-onset	AF	in	critically	ill	patients	from	165	
the	analysis.	Four	lacked	information	on	background	and	demographics	and	were	also	166	
excluded.	167	
46.6%	 of	 respondents	 were	 from	 District	 General	 Hospitals;	 a	 smaller	 proportion	168	
(38.5%)	worked	in	University	Hospitals	or	Tertiary	referral	centres.	The	admission	rate	169	
ranged	between	500	 and	2000	patients/year	 in	most	 centres,	 81.1%	of	 units	were	170	
mixed	ICUs	admitting	medical	and	surgical	patients	(Table	1).	171	
Most	respondents	(47.2%)	worked	on	units	with	11-20	staffed	beds	(level	2	and	level	172	
3).	 Our	 results	 indicate	 that	 mainly	 senior	 medical	 staff	 responded	 to	 the	 survey	173	
invitation,	with	Consultants	representing	71.8%	of	respondents;	53.9%	had	more	than	174	
10	years	of	experience	in	Critical	Care.	Anaesthesia	was	the	most	common	secondary	175	
specialty	stated	(83.9%)	(Table	2).	176	
Anti-arrhythmic	treatment	of	new-onset	AF	177	
39.5%	of	respondents	would	start	intervention	on	patients	with	fast	new-onset	AF	and	178	
stable	blood	pressure	at	a	heart	 rate	between	120	and	139	beats/min.	However,	a	179	
similar	 proportion	 of	 respondents	 (34.8%)	would	 treat	 all	 patients	who	 developed	180	
new-onset	 fast	 AF,	 independent	 of	 their	 heart	 rate,	 even	 if	 the	 blood	 pressure	181	
remained	stable.	54.7%	of	respondents	stated	that	the	primary	treatment	goal	of	new-182	
onset	AF	among	ICU	patients	with	stable	BP	without	a	known	cardiac	history	was	rate	183	
control,	while	40.3%	of	respondents	aimed	for	rhythm	control.	We	analysed	whether	184	
the	choosing	rate	control	versus	rhythm	control	as	primary	treatment	goal	influenced	185	
physicians’	views	on	heart	rate	at	which	they	would	intervene	(Table	2).	Although	a	186	
significantly	higher	percentage	(p<0.001)	of	physicians	who	stated	“Rhythm	control”	187	
as	 their	 primary	 treatment	 goal	 would	 intervene	 at	 any	 heart	 rate,	 the	 overall	188	
association	between	primary	treatment	goal	and	heart	rate	requiring	intervention	was	189	
only	moderate	(Cramer’s	V	=0.316).		190	
Amiodarone	was	by	far	the	most	commonly	used	anti-arrhythmic	for	treatment	of	191	
new-onset	AF	in	critically	ill	patients	(80.9%	of	answers),	followed	by	beta-blockade	192	
(11.6%)	(Figure	1).	193	
We	wanted	to	explore	the	primary	treatment	strategy	for	a	typical	critically	ill	patient	194	
using	a	case	vignette	of	a	patient	with	chest	sepsis,	who	develops	fast	new-onset	AF	195	
with	a	heart	rate	of	140-160	bpm.	The	patient	had	no	cardiac	history,	a	blood	pressure	196	
of	 100/60	 mmHg	 and	 received	 0.25	 mcg/kg/min	 noradrenaline.	 Most	 survey	197	
respondents	 opted	 for	 electrolyte	 supplementation	 to	 high	 normal	 level	 and	198	
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additional	 anti-arrhythmics	 (53.6%).	 23.8%	 of	 respondents	 advocated	 electrolyte	199	
supplementation	to	a	high	normal	level	only,	and	14.9%	opted	for	DC	cardioversion	200	
when	anti-arrhythmics	and	electrolyte	replacement	fail	to	achieve	rate	and/or	rhythm	201	
control.	 No	 one	 chose	 to	 perform	 DC	 cardioversion	 only	 (Figure	 2).	 In	 critically	 ill	202	
patients	with	new-onset	AF	74.3%	of	survey	respondents	aimed	for	serum	Potassium	203	
level	of	>4.5	mmol/l	and	59.7%	of	survey	respondents	aimed	for	serum	Magnesium	204	
level	of	1.0-1.2	mmol/l	(Figure	3).	Pharmacodynamics	properties	and	adverse	effect	205	
profile	were	leading	factors	for	choosing	anti-arrhythmic	treatment	for	new-onset	AF	206	
in	critically	ill	patients	(Figure	4).		207	
Anticoagulation	in	patients	with	new-onset	fast	AF:	208	
63.8%	of	respondents	stated	that	they	would	not	regularly	anti-coagulate	critically	ill	209	
patients	with	new-onset	 fast	AF,	while	30.8%	would	anti-coagulate	within	72	hours	210	
(Table	3a).	53.3%	of	all	survey	respondents	thought	that	subcutaneous	low	molecular	211	
weight	 heparin	 in	 therapeutic	 dose	 is	 appropriate	 for	 anti-coagulation	 and	 26,8%	212	
considered	intravenous	high	molecular	weight	heparin	as	appropriate,	provided	that	213	
no	 contra-	 indications	 for	 either	 substance	 were	 known	 (Table	 3b).	 Sub-analysis	214	
excluding	respondents	who	gave	“I	do	not	regularly	anti-coagulate	critically	ill	patients	215	
with	 new	 onset	 fast	 AF”	 as	 the	 only	 answer	 (136/362	 respondents),	 revealed	 that	216	
either	 low	 or	 high	molecular	 weight	 heparin	 was	 considered	 appropriate	 for	 anti-217	
coagulation	by	more	than	98%	of	physicians.	218	
68.0%	of	 survey	 respondents	did	not	use	 stroke	 risk	 scores	 routinely	 in	 critically	 ill	219	
patients	with	new-onset	AF	to	assess	the	need	for	anticoagulation.	30.9%	of	survey	220	
respondents	 thought	 that	 stroke	 risk	 scores	 inaccurately	 reflect	 the	 risk	of	embolic	221	
events	in	critically	ill	patients	with	new-onset	atrial	fibrillation	due	to	prothrombotic	222	
changes	associated	with	critical	illness.	47.0%	of	respondents	thought	that	modified	223	
risk	 scores	 should	 be	 developed	 for	 critically	 ill	 patients	 with	 new-onset	 atrial	224	
fibrillation	(Table	4).		225	
Approximately	half	of	the	respondents	(52.2%)	would	request	an	echocardiogram	in	226	
patients	with	new-onset	AF.	Only	a	small	minority	(3.3%)	would	use	transoesophageal	227	
echocardiography,	 while	 a	 large	 proportion	 (48.9%)	 would	 request	 a	 transthoracic	228	
echocardiography.	 39.2%	 of	 survey	 respondents	 did	 not	 routinely	 perform	229	
echocardiography	to	guide	treatment.	230	
Research	interest	amongst	intensivists	who	treat	patients	with	new-onset	AF	231	
85.4%	of	survey	respondents	would	consider	taking	part	in	a	clinical	trial	investigating	232	
treatment	of	new-onset	fast	AF	in	the	critically	ill.	In	the	setting	of	a	research	study	on	233	
general	 ICU	patients,	 amiodarone	 (74.0%)	 and	beta-blockers	 (55.8%)	were	 the	 two	234	
most	frequently	mentioned	pharmaceutical	treatments	to	be	investigated	for	critically	235	
ill	patients	with	new-onset	fast	AF.	There	was	a	divided	opinion	regarding	the	use	of	a	236	
8	
	
placebo	 arm	 (i.e.	 not	 treating	 new-onset	 AF	 with	 anti-arrhythmics	 or	 rate-limiting	237	
agents,	when	BP	 and	 cardiac	output	 are	 stable).	 In	 the	 setting	of	 a	 research	 study	238	
investigating	the	effectiveness	of	anti-arrhythmic	or	rate-limiting	agents	in	critically	ill	239	
patients	with	new-onset	fast	AF,	50.3%	of	respondents	would	not	accept	a	placebo	240	
arm.	241	
	242	
Discussion	243	
New-onset	 AF	 is	 the	 most	 commonly	 observed	 arrhythmia	 in	 critically	 ill	 patients	244	
(Artucio	&	Pereira	1990).	It	is	associated	with	a	worse	prognosis	(Champion	et	al.	2014;	245	
Chen	et	al.	2015;	Shaver	et	al.	2015)	and	longer	ICU	stays	(Duby	et	al.	2017;	Reinelt	246	
2001),	particularly	in	patients	with	sepsis	(Klein	Klouwenberg	et	al.	2017).	Despite	the	247	
large	number	of	patients	affected	and	potential	long-term	consequences	(Walkey	et	248	
al.	2014),	thorough	research	on	treatment	of	new-onset	AF	is	 lacking	(Walkey	et	al.	249	
2015).	Our	survey	revealed	two	areas	with	substantial	research	need:	Anti-arrhythmic	250	
treatment	of	new-onset	AF	and	anticoagulant	therapy.	251	
Prolonged	periods	of	elevated	heart	rate	are	associated	with	a	higher	risk	of	cardiac	252	
complications	(Sander	et	al.	2005).	A	retrospective	study	in	non-cardiac	ICU	patients	253	
found	that	37%	of	patients	with	new-onset	AF	suffered	from	hemodynamic	instability	254	
related	to	the	development	of	AF	(Kanji	et	al.	2012).	Intensivists	are	concerned	about	255	
complications	such	as	hypotension,	myocardial	ischemia	and	reduced	organ	perfusion,	256	
all	of	which	are	known	to	be	associated	with	new-onset	AF	with	a	high	conduction	rate.	257	
In	our	survey,	one	third	of	intensivists	would	treat	all	patients	with	new-onset	fast	AF,	258	
independent	 of	 their	 heart	 rate,	 even	 if	 the	 blood	 pressure	 remained	 stable,	259	
presumably	 in	an	attempt	 to	prevent	 these	potentially	harmful	events.	However,	a	260	
slightly	higher	proportion	(39.5%)	would	set	a	heart	rate	of	more	than	120	bpm	as	a	261	
treatment	threshold	in	haemodynamically	stable	patients.	262	
More	than	half	of	the	intensivists	who	participated	in	our	survey	aimed	for	rate	control	263	
as	the	primary	treatment	goal,	while	about	40%	prioritized	rhythm	control.	A	recent	264	
single-center,	 retrospective,	 cohort	 study	 described	 a	 higher	 mortality	 in	 septic	265	
patients	with	new-onset	AF	who	failed	to	convert	into	sinus	rhythm	(Liu	et	al.	2016).	266	
Rhythm	control	and	rate	control	have	both	been	used	as	outcome	measures	in	the	few	267	
therapeutic	 studies	 available	 in	 the	 literature,	 although	 there	 is	 no	 clear	 guidance	268	
whether	rate	or	rhythm	control	is	preferable	to	influence	overall	outcome	of	critical	269	
illness	(Liu	et	al.	2016).	270	
In	fact,	a	recent	systematic	review	on	new-onset	AF	in	non-cardiac	critically	ill	patients	271	
identified	only	five	studies,	which	compared	different	treatment	strategies	for	new-272	
onset	AF	in	critically	ill	patients	(Yoshida	et	al.	2015).	However,	only	one	of	the	studies	273	
was	 a	 randomised	 controlled	 trial.	 Therapies	 studied	 to	 date	 include	beta-blockers	274	
(Balser	 et	 al.	 1998;	 Meierhenrich	 et	 al.	 2010),	 Vernakalant	 (Arrigo	 et	 al.	 2014),	275	
9	
	
Diltiazem	(Balser	et	al.	1998),	DC	cardioversion		(Arrigo	et	al.	2015;	Kanji	et	al.	2012;	276	
Mayr	et	al.	2003;	Meierhenrich	et	al.	2010;	Seguin	et	al.	2006),	Amiodarone	(Balser	et	277	
al.	1998;	Kanji	et	al.	2012;	Meierhenrich	et	al.	2010;	Seguin	et	al.	2006;	Sleeswijk	et	al.	278	
2008),	 Sotalol	 (Kanji	 et	 al.	 2008)	 and	digitalis	 glycosides	 (Meierhenrich	 et	 al.	 2010;	279	
Seguin	et	al.	2006).	The	need	to	perform	research	on	treatment	of	new-onset	AF	in	280	
critically	 ill	 patients	 is	 reflected	 by	 the	 high	 percentage	 (85%)	 of	 intensivists	 who	281	
declared	an	interest	in	participating	in	such	research.		282	
In	our	survey,	amiodarone	was	the	preferred	pharmaceutical	treatment	for	more	than	283	
80%	of	intensivists	who	participated,	potentially	because	it	 is	associated	with	fewer	284	
haemodynamic	effects	compared	to	beta-blockers	and	calcium	channel	blockers	(Delle	285	
Karth	et	al.	2001).	Unfortunately,	evidence	supporting	its	use	in	critically	ill	patients	is	286	
limited	to	small	single-centre	studies	only	(Delle	Karth	et	al.	2001;	Shibata	et	al.	2016).		287	
NICE	 guidelines	 recommend	 either	 a	 standard	 beta‑blocker	 or	 a	 rate-limiting	288	
calcium‑channel	blocker	as	initial	monotherapy	for	patients	with	new-onset	AF	(Jones	289	
et	al.	2014)	or,	for	patients	who	are	sedentary,	digoxin	monotherapy.	These	guidelines	290	
have	been	developed	for	patients	with	AF	in	the	general	population,	but	may	not	be	291	
transferable	to	the	intensive	care	setting	due	to	different	predisposing	factors	for	AF	292	
in	 critically	 ill	 patients.	 In	 particular,	 new-onset	 AF	 has	 been	 associated	 with	293	
inflammation	and	occurs	in	up	to	46%	of	patients	with	septic	shock	(11).	Patients	with	294	
septic	shock	who	developed	new-onset	AF	showed	a	continuous,	significant	increase	295	
in	CRP	plasma	levels	before	occurrence	of	AF	(Meierhenrich	et	al.	2010).	Further	risk	296	
factors	 for	 new-onset	AF	 in	 the	 critically	 ill	 include	 inotropic	 support	 (Seguin	 et	 al.	297	
2006),	advanced	age	and	high	scores	of	severity	of	disease	(Yoshida	et	al.	2015).	In	the	298	
United	Stated,	where	diltiazem	 is	available	 for	 intravenous	administration,	calcium-299	
channel	blockers	were	the	most	frequently	used	drugs	to	treat	new-onset	AF	during	300	
sepsis	 (Walkey	et	 al.	 2016),	 although	 the	use	of	beta-blockers	was	 associated	with	301	
improved	mortality	in	a	propensity	analysis.	302	
About	a	quarter	of	respondents	would	choose	electrolyte	supplementation	to	a	high	303	
normal	level	only,	while	more	than	half	(53.6%)	would	add	anti-arrhythmics	or	rate-304	
limiting	agents	as	a	primary	treatment	strategy.	The	use	of	 intravenous	magnesium	305	
sulphate	 bolus	 application	 followed	by	 continuous	 infusion	 achieved	 conversion	 to	306	
sinus	rhythm	or	decrease	in	heart	rate	<110	bpm	in	16	of	29	patients	(55%)	in	a	small	307	
prospective	 study	 (Sleeswijk	 et	 al.	 2008),	 while	 magnesium-amiodarone	 step-up	308	
therapy	achieved	a	conversion	rate	of	more	than	90%	within	24	h	in	a	cohort	of	mixed	309	
critically	 ill	 patients.	 Although	 these	 findings	 suggest	 that	 amiodarone,	magnesium	310	
sulphate,	or	the	combination	thereof	might	be	effective	to	prevent	or	treat	new-onset	311	
AF,	more	 studies	 are	 needed	 to	 evaluate	 the	efficiency	 and	 safety	 profile	 of	 these	312	
drugs	in	the	general	critically	ill	population.	313	
10	
	
Haemodynamic	stability	during	and	immediately	after	the	onset	of	AF	and	long-term	314	
stroke	 risk	are	often	dependent	on	underlying	 left	 ventricular	 systolic	 and	diastolic	315	
function.	Echocardiography	provides	useful	 information	on	right	and	left	ventricular	316	
function	as	well	as	size	of	both	atria	to	determine	optimal	treatment	in	patients	with	317	
acute	haemodynamic	deterioration.	Although	nearly	half	of	 the	respondents	would	318	
request	 a	 transthoracic	 echo,	 a	 large	 proportion	 (39%)	 does	 not	 routinely	 use	319	
echocardiography	to	guide	management	in	this	patient	cohort.	320	
	321	
NICE/ACC/AHA/ESC	 practice	 guidelines	 recommend	 routine	 anti-coagulation	 of	322	
patients	 with	 new-onset	 AF	 depending	 on	 their	 individual	 risk	 of	 thromboembolic	323	
events	 using	 established	 scores	 such	 as	 CHADS2	 and	 CHA2DS2-VASc	 (Jones	 et	 al.	324	
2014).	However,	the	risk	of	stroke	and	thromboembolic	events	in	critically	ill	patients	325	
who	 develop	 new-onset	 AF	 has	 been	 evaluated	 in	 only	 very	 few	 studies.	 A	 recent	326	
prospective	observational	study	revealed	that	both	CHADS2	and	CHA2DS2-VASc	are	327	
predictive	of	thromboembolic	events	in	the	critical	care	setting	(Champion	et	al.	2014),	328	
with	 a	 CHADS2	 score	 of	 4	 or	 higher	 being	 the	most	 accurate	 threshold.	 In	 a	 large	329	
retrospective	study	on	more	than	49	000	patients	with	sepsis	Walkey	et	al	(Walkey	et	330	
al.	 2011)	 described	 that	 new-onset	 AF	 during	 severe	 sepsis	 was	 associated	with	 a	331	
nearly	four-fold	increased	risk	of	in-hospital	ischemic	stroke,	with	threefold	greater	in-332	
hospital	stroke	rates	compared	with	patients	without	AF	during	sepsis.	Despite	this	333	
adverse	risk	profile,	63.8%	of	intensivists	participating	in	our	survey	stated	that	they	334	
would	not	regularly	anti-coagulate	critically	ill	patients	with	new-onset	fast	AF,	while	335	
30.8%	of	respondents	would	anti-coagulate	within	72h.	Intensivists	may	be	reluctant	336	
to	commence	therapeutic	anticoagulation	in	critically	ill	patients	with	new-onset	AF	337	
because	the	risk/benefit	ratio	of	anticoagulation	during	acute	critical	 illness	is	often	338	
unclear.	Critically	ill	patients	may	be	at	substantially	increased	risks	of	severe	bleeding	339	
due	 to	 thrombocytopenia,	 renal	 failure,	 liver	 failure,	 invasive	 devices,	 and	340	
unscheduled	 procedures	 (Walkey	 et	 al.	 2015),	 and	 bleeding	 complications	 such	 as	341	
gastrointestinal	 haemorrhage	 or	 intracerebral	 bleeds	 are	 common	 (Darwish	 et	 al.	342	
2013).	Currently	recommended	scores	for	stratification	of	thromboembolic	risk,	such	343	
as	the	CHADS2	and	CHA2DS2VASc	scores,	and	the	scores	for	hemorrhagic	risk,	like	the	344	
HAS-BLED	score	have	limitations	when	applied	in	critically	ill	patients	(Ferreira	et	al.	345	
2015).	Hence	scores	developed	to	assess	the	stroke	risk	in	the	general	population	with	346	
AF,	are	not	routinely	used	by	more	than	two	thirds	of	intensivists	who	participated	in	347	
our	survey.	30.9%	of	survey	respondents	felt	that	the	currently	recommended	stroke	348	
risk	scores	inaccurately	reflect	the	risk	of	embolic	events	in	critically	ill	patients	with	349	
new-onset	AF	due	to	prothrombotic	changes	associated	with	critical	illness.	Nearly	half	350	
of	the	respondents	(47.0%)	thought	that	modified	risk	scores	should	be	developed	for	351	
critically	 ill	 patients	 with	 new-onset	 atrial	 fibrillation	 to	 take	 into	 account	 such	352	
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alterations	in	the	coagulation	system	in	critically	ill	patients.	In	an	attempt	to	address	353	
this,	a	multi-centre	observational	study	has	been	set	up	to	further	identify	clinical	and	354	
echocardiographic	risk	factors	for	thromboembolic	events	in	critically	ill	patients	with	355	
new-onset	AF	(Labbe	et	al.	2015).	356	
Importantly,	 decisions	 to	 anti-coagulate	 patients	 with	 new-onset	 AF	 during	 critical	357	
illness	may	influence	the	stroke	risk	beyond	their	critical	care	admission.	More	than	358	
half	of	patients	with	new-onset	AF	have	a	later	recurrence	of	AF	(Walkey	et	al.	2014).	359	
Patients	with	new-onset	AF	during	acute	illness	also	have	elevated	long-term	risks of	360	
stroke.	 A	 proposed	 approach	 to	 long-term	 management	 of	 patients	 who	 develop	361	
periods	of	AF	during	critical	illness	includes	re-assessment	for	rhythm	and	heart	rate	362	
surveillance,	 cardiovascular	 comorbidities,	 thyroid	 function,	 stroke	 risk	 and	 should	363	
include	echocardiography	and	patients’	preferences	(Walkey	et	al.	2015)	to	manage	364	
stroke	 and	 cardiovascular	 risk	 after	 ICU	 discharge.	 However,	 data	 are	 lacking	 to	365	
estimate	 rates	 of	 severe	 bleeding	 versus	 stroke	 risk	 with	 use	 of	 systemic	366	
anticoagulation	 during	 critical	 illness.	 Due	 to	 this	 uncertainty,	 a	 recent	 review	367	
concluded	that	routine	anticoagulation	for	new-onset	AF	among	critically	ill	patients	368	
with	elevated	bleeding	risk	cannot	be	recommended	as	a	treatment	where	benefits	369	
outweigh	risks	(Walkey	et	al.	2015).		370	
Our	survey	has	several	limitations.	We	only	approached	members	of	the	Intensive	Care	371	
Society	(ICS),	due	the	necessity	of	an	accessible	and	up-to-date	email	distribution	list.	372	
Approximately	two	thirds	of	practising	intensivists	in	the	UK	are	members	of	the	ICS,	373	
indicating	that	a	significant	proportion	of	intensivists	were	not	given	the	opportunity	374	
to	express	their	views.	Given	the	 low	overall	 response	rate,	non-response	bias	may	375	
also	have	 influenced	our	 results.	However,	acute	care	physicians	are	a	professional	376	
group	with	reportedly	low	survey	response	rates	(Champion	&	Deye	2017),	likely	due	377	
to	time	constraints	and	high	workload.	This	short	online	survey	consisted	of	a	limited	378	
number	 of	 general	 questions	 only	 to	 allow	 rapid	 completion.	Hence,	we	 could	 not	379	
thoroughly	explore	background	knowledge	and	experience	of	the	respondents	 in	 in	380	
this	complex	 field.	 In	particular,	 treatment	strategies	 in	 relation	to	cardiac	 function	381	
and	 combination	 of	 therapies	 such	 as	 cardioversion	 in	 addition	 to	 anti-arrhythmic	382	
substances	could	not	be	evaluated.		383	
Our	survey	focused	on	general	management	of	new-onset	atrial	fibrillation	in	critical	384	
care;	 specific	 subgroups	 of	 patients	 including	 those	 after	 cardiothoracic	 surgery	 or	385	
with	primary	cardiac	diagnoses	were	not	specifically	addressed.	These	patient	cohorts	386	
may	 require	 separate	 investigations	 because	 of	 different	 pathomechanisms	 and	387	
treatment	requirements.	388	
Conclusions:	389	
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	We	identified	a	high	variation	in	the	use	of	anti-arrhythmic	treatment	in	critically	ill	390	
patients	with	new-onset	AF,	which	can	be	explained	by	the	lack	of	both	high-quality	391	
studies	and	evidence	to	guide	the	management	of	new-onset	AF	in	the	critical	care	392	
setting.	Intensivists	expressed	a	substantial	interest	in	research	in	this	area,	making	it	393	
a	priority	for	future	clinical	trials.	Interventional	and	observational	studies	will	have	to	394	
address	the	benefits	of	pharmacotherapy	for	new-onset	AF	in	critically	ill	patients	and	395	
the	effect	of	individual	drug	choices	on	patient	short	and	long-term	outcomes.	Further	396	
work	is	also	required	to	describe	and	assess	the	risk/benefit	ratio	of	thromboembolic	397	
prophylaxis	in	critically	ill	patients	with	new-onset	AF.	398	
	399	
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